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Jeffrey Chell,1 Edward L. Snyder10Hematopoietic cell transplantation (HCT) is the only known curative therapy for many patients with life-
threatening hematologic and oncologic diseases. It is estimated that the National Marrow Donor Program
(NMDP) will facilitate 10,000 transplants by 2015, double the current number. To better understand the ex-
isting personnel and center infrastructure for HCT in the country and to address system capacity challenges
to the future growth of HCT, the NMDP convened a diverse group of stakeholders and thought leaders rep-
resenting HCT physicians, physician assistants, nurse practitioners, nurses, pharmacists, other healthcare
providers, HCT program directors, hospital administrators, payors, and professional organizations. Working
groups were formed to identify: capacity issues because of shortages in human resources, structural con-
straints, and patient access barriers including diversity and healthcare disparity challenges; recommendations
to address challenges; and stakeholders to engage. This report details the deliberations and recommenda-
tions of a national symposium, ‘‘Hematopoietic Cell Transplantation in 2020: A Health Care Resource and
Infrastructure Assessment,’’ held in September 2010.
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Hematopoietic cell transplantation (HCT) is the
only known curative therapy for many patients with
life-threatening hematologic and oncologic diseases.
Approximately 20,000 autologous and allogeneic
HCT are performed in the United States each year
[1]. It is anticipated that need and utilization of
HCT will continue to grow in the future [2]. The Na-
tional Marrow Donor Program (NMDP) estimates
that it will facilitate 10,000 transplants by 2015, double
the current number. Several factors are expected to
contribute to the increase in demand for HCT. These
include increasing utilization of reduced-intensity
conditioning regimens, increasing diversity and avail-
ability of unrelated donors and umbilical cord blood
as graft sources, improvements in supportive care,
and expanding indications for HCT.
The most critical system capacity barriers to the
future growth ofHCT in theUnited States involve hu-
man resources, structural constraints, and patient ac-
cess barriers. Human resource constraints include
a projected shortage of physicians, physician assistants,
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healthcare professionals who make up the HCT work-
force [3-10]. Structural constraints include availability
of adequate facilities, efficient and safe care delivery
models, and the infrastructure required to meet the
demand of HCT [11,12]. Key patient access barriers
include availability of suitably matched donors or cord
blood units, transportation and financial burdens, lack
of caregiver support, and limited access to transplant-
related patient information [13,14]. Capacity issues
may also limit access to HCT for minorities and
underserved populations. The increasing number of
transplant survivors will be an added burden to
the transplant centers providing care to patients
undergoing transplantation as well as to the entire
healthcare system. Furthermore, increasing access to
transplantation for medically underserved patient
populations such as low-income individuals, underin-
sured persons, and racial and ethnic minorities is a crit-
ical area yet to be addressed. Although data are
limited, studies project a future shortage of transplant
physicians and center capacity in the United States
[2,3,11,12]. A future shortage of advanced practice
and nursing professionals in the United States is also
expected [6-10].
To better understand the existing personnel and
center infrastructure for HCT in the country and to
address system capacity challenges to the future
growth ofHCT, theNMDP organized a series of mul-
tiyear symposia to collaboratively develop creative op-
tions for complex issues affecting the delivery of HCT.
Participants were comprised of key professionals, aca-
demic organizations, experts,and stakeholders. This
report details the deliberations and recommendations
of a national symposium, ‘‘Hematopoietic Cell Trans-
plantation in 2020: AHealth Care Resource and Infra-
structure Assessment,’’ held in September 2010.DELIBERATIVE PROCESS
Presymposium
The NMDP convened a diverse group of stake-
holders and thought leaders representing HCT physi-
cians, physician assistants, nurse practitioners, nurses,
other healthcare providers, HCT program directors,
hospital administrators, payors, and professional orga-
nizations. Based on their area of expertise, each stake-
holder was assigned to 1 of 6 working groups:
Physician Workforce, Advanced Practice Profes-
sionals Workforce, Nursing Workforce; Care Deliv-
ery Model; Facilities/Bed Capacity; and Financial.
The workgroups convened via monthly teleconfer-
ences over the 8 months before the Symposium—
Year I. Each group systematically conducted an
analysis of its topic area, which included identifying
capacity issues including diversity and health care dis-parity challenges; recommendations to address chal-
lenges; potential capacity impact; stakeholders to
engage; resources needed; barriers to carrying out rec-
ommendations and metrics.
By utilizing a deliberative process, the NMDP was
able to effectively facilitate a well-planned national
collaborative approach to address HCT system capac-
ity challenges to the current utilization and future
growth of HCT therapy.
Working Group Surveys
To verify whether the working group deliberations
reflected industry perspectives, the Physician, Nursing,
and Advanced Practice Professional (APP) Workforce
Working Groups and the Facilities/Bed Capacity
WorkingGroup conducted informalWeb surveys. Sur-
veys were distributed to HCT physicians, nurses, ad-
vanced practice professionals, and transplant center
administrators who aremembers of the American Soci-
ety of Blood and Marrow Transplantation (ASBMT),
the Oncology Nursing Society (ONS), or the NMDP
network. The goal of the surveys was to: (1) ascertain
perspectives on the capacity of theUnited States health-
care system to support the needs of HCT through the
year 2020, and (2) characterize system capacity chal-
lenges that will prevent optimal utilization of HCT.
Symposium
Working Groups first prioritized their respective
findings. Subsequently, their deliberations on the
United States HCT system’s ability to meet the rising
demand of HCT therapies were presented at the
NMDP-sponsored ‘‘Hematopoietic Cell Transplanta-
tion in 2020: A Health Care Resource and Infrastruc-
ture Assessment Symposium’’ in Chicago, IL on
September 15-16, 2010. The 1.5 day meeting was at-
tended by nearly 100 national stakeholders and
thought leaders. In total, 46 academic, professional,
patient advocacy organizations, and transplant centers
across the United States were represented, as well as 2
government agencies (Table 1).
The goal of the Symposium—Year I was to under-
stand the workforce and capacity challenges of the cur-
rent healthcare system to enable full access to HCT
therapy for all patients who are in need of this curative
therapy. Presentations at the Symposium encompassed
working group findings, audience polling, and dia-
logue. Round table discussions focused on the devel-
opment of strategies to address challenges during
Year II.
Challenges and Recommendations by Working
Group
The challenges and prioritized recommendations
made by the Working Groups are summarized in
Table 2.
Table 1. Organizations, Transplant Centers and Government Agencies Represented at the Hematopoietic Cell Transplantation in
2020 Symposium—Year I
American Society for Blood and Marrow Transplantation National Institutes of Health
Association of Oncology Social Work Northwestern Memorial Hospital
Association of Pediatric Oncology Social Workers Oncology Nursing Society
Banner Health Optum Health
CancerCare OptumHealth Care Solutions
Cedars-Sinai Medical Center Oregon Health and Science University
Children’s Mercy Hospital Partners HealthCare
Center for International Blood and Marrow Transplant Research Roswell Park Cancer Institute
CIGNA LifeSOURCE Transplant Network Seattle Cancer Care Alliance
City of Hope National Medical Center South Texas Blood & Tissue Center
Dana-Farber Cancer Institute St. Luke’s Episcopal Hospital
Duke University Medical Center Stanford University Medical Center
Florida Hospital University of Alabama in Birmingham
Fred Hutchinson Cancer Research Center University of California San Francisco
Health Interactions University of Iowa Hospitals
Health Resources & Services Administration University of Miami
Kaiser Permanente University of Minnesota Medical Center, Fairview
LifeTrac Network University of Nebraska Medical Center
Loyola University Medical Center University of Oklahoma Health Sciences Center
Massachusetts General Hospital/North Shore Cancer Center University of Texas, MD Anderson Cancer Center
Mayo Clinic University of Utah
Medical College of Georgia Washington University School of Medicine in St. Louis
H Lee Moffitt Cancer Center and Research Institute WellPoint, Inc
National Marrow Donor Program Yale University/Yale-New Haven Hospital
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The Physician Workforce Working Group’s
deliberations focused on recruitment of HCT physi-
cians in training, retention of currentHCT physicians,
nonpatient care areas of academic medicine including
administration, mentoring and clinical research, gen-
erational differences in how physicians view work
hours and compensation, increasing workforce diver-
sity, and physicians’ influence on the care delivery
model. Major barriers identified included the current
and projected shortage of HCT physicians through
2020, HCT physician recruitment, and retention
with a specific focus on work/life balance issues.
The Working Group emphasized the need to
clearly characterize the HCT physician workforce.
Currently, a comprehensive database identifying
HCT physicians does not exist. The Working Group
recommendations are to: create a comprehensive direc-
tory ofHCTphysicians and centers in theUnited States
to establish a valid benchmark on the number of HCT
physicians in the field; and conduct a census of HCT
physicians to identify workforce demographics and de-
termine the rateofdepartingHCTphysicians eachyear.
The working group also recognized the need to
recruit more HCT physicians. The ASBMT recently
reported 2226 adult and pediatric transplant physi-
cians would be required by the year 2020 [4]. After
taking into account projected physician growth (ad-
ministrative and regulatory requirements, long-term
survivorship care, etc.) and retirement rates, this repre-
sents a shortage of 1358 new transplant physicians by
the year 2020. These calculations did not take into ac-
count the potential for greater utilization of unrelated
donors and umbilical cord blood or future new thera-
peutic uses of HCT.Recruitment of physicians to the field of HCT is
challenging as certification does not exist for this sub-
specialty. Limited effort has been made to create early
awareness of HCT as a career path option for medical
students and residents. Recommendations for recruit-
ing physicians to HCT included: establish a complete
directory of HCT training programs in the United
States; conduct focus groups to identify barriers to
HCT physician recruitment and training; develop an
HCT training curriculum; assess the need for funding
of HCT internship and fellowship opportunities, par-
ticularly to provide support for HCT clinical training
if such training is performed outside the context of an
Accreditation Council for Graduate Medical Educa-
tion fellowship training program; promote teaching
among HCT physicians to increase exposure to
HCT for medical students and residents; and partner
with medical schools, residency and fellowship pro-
grams to facilitate exposure to HCT ambulatory and
hospital-based clinical training programs.
In addition to recruitment, retention of HCT phy-
sicians was also identified as a priority focus area by the
working group. Work/life balance was felt to be a key
retention challenge. To improve work/life balance
among HCT physicians, the working group recom-
mended: the development of a campaign to sensitize
HCT administration and leadership to key factors
driving job satisfaction; decreasing workload through
the increased utilization of advanced practice profes-
sionals and multidisciplinary teams and the adoption
of alternate practice models; increasing compensation
based on established compensation benchmarks for
HCT physicians; and the promotion of career devel-
opment within HCT programs by providing formal
mentorship to HCT physicians.
Table 2. Hematopoietic Cell Transplantation (HCT) in 2020: System Capacity Challenges and Recommendations
Identified System Challenges Recommendations
Physician Workforce
 Physician shortage
– Recruitment
– Retention
– Work environment
 Workforce diversity
 Validate work effort benchmarks
 Conduct transplant physician census to characterize workforce
 Create a directory of HCT training and fellowship programs
 Establish a faculty membership training program
 Develop models for part-time positions
 Target medical schools and residency programs as part of a recruitment strategy
Advanced Practice Professional (APP) Workforce
 Care team work models
 APP shortage
– Recruitment
– Retention
– Work environment
 Workforce diversity
 Better define the APP role within HCT
 Increase exposure to HCT as a career path for students and practicing APPs
– Develop ‘‘Blood and Marrow Transplant (BMT) 101’’ presentation for APP graduate programs
 Improve quality of work life
– Identify ways to prevent burnout and better characterize the APP workload
 Engage administration in exploring compensation and benefits package options to support
continuing education, professional memberships, etc.
 Establish national Physician Assistant ASBMT SIG*
 Partner with ASBMT* to create orientation and education standards for APPs entering the field
Nursing Workforce
 Nursing shortage
– Recruitment
– Retention
– Work environment
 Educational needs
 Workforce diversity
 Partner with nursing organizations to increase exposure to HCT nursing by promoting:
– Student internship/externship programs
– Successful models of career mentorship programs
– ONS* ‘‘Fundamentals of Blood and Marrow Transplant’’ Web course
– Identify funding sources for HCT nurse scholarship(s) and Professional development/
continuing education
 Explore successful models used in transplant centers and other clinical nursing areas to address:
– Work/life balance, compassion fatigue, and moral and ethical distress
 Increase access to transplants for minority/ethnic and medically underserved populations:
– Collaborate with NMDP Diversity advisory group to define and develop measures
– Recruit and retain nurses interested in and their capacity to serve underserved populations
Facilities/Bed Capacity
 Current capacity limitations
– Inpatient, outpatient, infusion therapy, etc.
 Distribution of HCT beds in the United States
 Care delivery model impact on physical space
requirements
 Increase in patient volume
– Demand on patient care/support services
– Shortage of temporary patient housing
near the transplant center
 Collect data from transplant programs
– Provide trend data on growth of transplants to support expansion initiatives
– Identify best practices to emulate
 Partner closely with Care Delivery Model Working Group
– Establish specific elements of care models
– Centers with high patient volume per bed as benchmark of efficiency and effectiveness
 Assist expansion planning by disseminating success stories, partnering with program
administrators or through use of external consultants
 Create a data set of growth models
 Help in developing measures of successful growth
Care Delivery Model
 Late timing for referral to transplant consultation
 Insufficient HLA typing at time of diagnosis
 Inadequate caregiver support
 Coordination of post-transplant patient care
 Transition to outpatient care model requires
optimal workflows
 Effective use of Residents and Fellows on
the care team
 Work with professional medical organizations to highlight optimal transplant timing
– Use payor data
– NMDP* Network Engagement team to inquire about late referrals on site visits
 Develop mechanism for patients’ physicians to access patient records
 Explore models for providing posttransplant care (eg, telemedicine, satellite clinics)
 Partner with Medicare/payors to structure reimbursement care in a variety of settings
 Identify housing options near transplant center
 Provide recommendations on staffing and design of outpatient facilities
 Develop patient and caregiver education materials and training programs
Financial
 Benefits vary significantly and are inadequate
– Financial barriers for patients
 Medicaid transplant benefits
– Vary significantly and inadequate in many states
 Medicare coverage and reimbursement
– Inadequate
– Growing problem as patient volume increases
 Inadequate search coverage
 Identify an essential set of HCT benefits which includes all components of transplant
 Develop a standard list of transplant codes and coding guidance
 Review utilization management/authorization processes for potential areas to streamline
procedures
– Reduce administrative delays on both sides
 Plan outreach strategies to all types of payors (eg, self-funded accounts, reinsurers and health
plans)
– Provide tools and information for decision making
*American Society for Blood and Marrow Transplant special interest group (ASBMT SIG); National Marrow Donor Program (NMDP); Oncology Nurs-
ing Society (ONS).
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The APP Workforce Working Group’s discus-
sions centered on increasing awareness ofHCT as a ca-
reer path option; continuing education needs for nurse
practitioners (NP) and physician assistants (PA); prac-tice models and professional development for APP; en-
gagement of physicians and administration to address
recruitment and retention challenges; and collabora-
tion with professional organizations to increase the di-
versity of the APP workforce.
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veloping innovative practice models that incorporate
APP into the HCT care team; specific recommenda-
tions for addressing practice models were: conduct
an analysis of time demand and workload among
APP; increase effective utilization of support staff in
the healthcare team practice model to allow APP to
function at their highest level of expertise; and de-
velop/incorporate tools to streamline administrative
tasks such as documentation, writing letters of neces-
sity, and obtaining insurance authorizations. APP
face challenges regarding scope of practice. The work-
ing group recommendation is to better define the role
of APP in HCT to increase efficiency of practice and
care delivery models.
A future shortage of APP is also projected [6-10],
which will further strain the HCT workforce. The
number of NP graduates declines by 4.5% each year
[8]; although there has been growth in the number of
PA graduates and a call to regularly include PA in dis-
cussions on the division of medical labor, given the ex-
tent of the physician shortage, it is projected that there
will not be an adequate number of PA to fill the gap
[9,10]. Recruitment and retention of APP in HCT is
an important component to addressing workforce
shortages. Key challenges to increasing the capacity
of the APP workforce include optimizing practice
models, recruiting PA and NP students to the field
of HCT, and retention of current APP.
Recommendations for recruitment strategies to
increase exposure to HCT in graduate programs
included: create an introductory HCT lecture;
develop and disseminate a brochure on HCT as
a career option targeted to students and APP;
encourage HCT centers to offer clinical rotations
and mentorship programs for APP students; and
identify APP champions willing to act as mentors/
preceptors. Mentoring students will yield long-term
results to the HCT field [15]. Improving the work en-
vironment and work/life balance are key strategies for
retention of HCTAPP. To address work environment
challenges, the Working Group recommended: en-
courage the use of staffing models, which include pe-
riods of ‘‘decompression’’ time off and offer flexible
scheduling options based on best practices; create
patient acuity guidelines for ratio of patients to APP;
and develop HCT orientation and education
standards.Nursing Workforce
Topic areas within scope for the Nursing Work-
forceWorking Group centered on education for allied
health professionals caring for HCT patients; recruit-
ment and retention of nurses in general and specifically
for oncology/HCT, including a specific focus on: di-
versity in the workforce; shortages of nursing precep-tors; the nursing viewpoint of the HCT care model;
the perception of transplantation among nurses; and
generational differences among nursing staff regarding
their approach to work.
Through Working Group deliberations, key chal-
lenges to building the capacity of the HCT nursing
workforce were identified: recruitment and retention
of HCT nurses; improving the work environment;
meeting educational needs; and increasing workforce
diversity.
As in theHCTphysician andAPPworkforces, a fu-
ture shortage of nursing professionals in the United
States is expected. Studies show that the nursing short-
age is projected to grow to 260,000 registered nurses
by 2025 [7,8]. In addition to an increasing demand
for transplant, this shortage will occur because of the
aging population of practicing nurses, increasing
retirement rates and difficulty in increasing
enrollment rates in nursing schools. An adequate
number of well-trained nurses is crucial to successful
HCT outcomes, and nursing shortages will negatively
impact future utilization of HCT.
To mitigate these challenges, the Working Group
recommended recruitment strategies including: devel-
opment of an HCT course through the ONS for basic
content and providing more advancedHCT education
at the BMT Tandem Meetings; encourage HCT
programs to hire nursing students as technicians/
assistants; promote the utilization of internship/
externship programs; implement an ‘‘outreach cam-
paign’’ to increase awareness of HCT as a career
path option targeted to students; engage the Oncology
Nursing Certification Corporation in creating an
HCT Certification as a subspecialty of Oncology;
and identify available funding sources for HCT nurse
scholarships.
Retention challenges impact the staffing mix in re-
gard to HCT experience and can result in less than op-
timal quality of healthcare delivery. The Working
Group recommended the following retention-
focused initiatives: explore successful models used in
transplant centers and other clinical nursing areas to
address work/life balance, compassion fatigue, and
moral and ethical distress; educate HCT nurses and
leadership on the importance of incorporating healthy
living habits and support services in the work environ-
ment; identify funding sources for professional devel-
opment and continuing education opportunities; and
facilitate the implementation of formal mentorship
programs in transplant centers.
In order to increase access to HCT for medically
underserved populations, it is essential to recruit and
retain nurses interested in and having the capacity to
serve these communities. The Working Group will
seek recommendations from the National Coalition
of Ethnic and Minority Nurse Associations for im-
proving diversity in HCT nursing workforce.
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of advances in HCT science. Recommendations for
meeting the educational needs of HCT nurses in-
cluded promoting the ONS ‘‘Hot Topics’’ discussion
forums and the NMDP ‘‘Advances in Transplanta-
tion’’ newsletter for nurses as well as the introductory
Web-based course discussed previously. It is critical
for HCT program administrators and nurse managers
to support continuing education for nurses in this field.Facilities/Bed Capacity Working Group
The Facilities/Bed Capacity Working Group con-
firmed that variations exist in the distribution of HCT
beds across the United States. Some transplant centers
are at or over capacity with their inpatient beds, outpa-
tient clinics, and infusion beds [2]. Further research is
needed to: assess regional variations in capacity; iden-
tify centers with high patient transplant volume per
bed rate; further understand best practices in care de-
livery models; advocate for capacity expansion in
underserved markets; and provide resources to trans-
plant center administrators for educating hospital ad-
ministrators about the need for expansion.
The Working Group noted that changes in care
delivery models have the potential to impact center fa-
cilities and bed capacity. To better understand this im-
pact, the Working Group recommended: identify care
delivery model best practices at transplant centers with
high patient transplant volume per bed rate and opti-
mal patient outcomes; and describe the potential im-
pact on future facility needs when innovative care
delivery models are developed and implemented.
One of the consequences of increasing patient vol-
ume at transplant centers is the increased demand on
all other patient care and support service areas. The
Working Group suggested that centers involve all pa-
tient care and support service stakeholders in early
stages of plans for expansion; thus, all facets of the pro-
gram can be readied for serving more patients.
Shortage of temporary housing for patients near
the transplant center is a common barrier to discharge
from hospital to the outpatient clinic. Further research
is needed to systematically assess when delays in inpa-
tient discharge are attributed to lack of temporary
housing availability near the transplant center. Part-
nering with patient housing resources such as local ho-
tel chains in the early stages of expansion plans will
ensure temporary lodging availability and minimize
discharge delays.Care Delivery Model Working Group
The Care DeliveryModelWorking Group’s scope
of work spanned from diagnosis through long-term
survivorship, including topic areas of: physician refer-
ral, pretransplant evaluation, acute phase of transplanttreatment model, posttransplant care, and long-term
survivorship.
Key challenges to ensuring transplant candidates’
ability to proceed to transplant at the most optimal
time for treatment of their disease include: late referral
to a transplant center; insufficient human leukocyte
antigen (HLA) typing completed at time of diagnosis;
and lack of available caregiver support.
To address late referral, the Working Group rec-
ommended: work with professional medical organiza-
tions (eg, American Society of Hematology, American
Society of Clinical Oncology) to draw attention to the
Recommended Timing for Transplant Consultation,
a set of guidelines for transplant consultation devel-
oped jointly by the NMDP and the ASBMT and based
upon current clinical practice and the medical litera-
ture including comprehensive evidence-based reviews
[16]; and develop strategies to further engage physi-
cians in the adoption of these guidelines.
The lack of sufficient HLA typing at diagnosis can
impact patient outcomes. Recommendations to ad-
dress access to HLA typing at the most optimal time
in the treatment decision course included: develop
a consensus on diseases where HLA typing is reim-
bursed when completed at time of diagnosis; draft
guidelines for health plans recommending reimburse-
ment of HLA typing at diagnosis for applicable dis-
eases; and educate the hematologists/oncologists who
refer patients for HCT on the importance of and logis-
tics for completing typing at diagnosis.
Posttransplant patients who return to homes that
are geographically far from the transplant center may
be seen by local primary care physicians and emer-
gency room departments for complications related to
transplant. Suboptimal posttransplant care may occur
when these local care providers encounter less than ad-
equate access to the patient’s medical records and
transplant consultation services. Furthermore, trans-
plant recipients generally represent a very small pro-
portion of patients seen in these practices and
providers may not be comfortable in caring for trans-
plant recipients. Recommendations to enhance effi-
ciency, expertise, and logistics of caring for patients
posttransplant included the development of: patient
and clinician posttransplant guidelines that can be
used by transplant centers to improve communication
with primary care and hematology/oncology physi-
cians; and mechanisms for patients and treating physi-
cians to access transplant patient health information.
The Working Group also recommended leveraging
patient care by coordinating care plans that have
been developed independently by payors, pharmacists,
and transplant physicians.
Patients do not always have the ability to assemble
a sufficiently skilled caregiver team by themselves [14].
The working group recognized that a lack of adequate
caregiver support can be a barrier to proceeding with
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sented by the working group to support theHCT care-
giver included: develop a caregiver education program
or assess existing programs for broad adoption; iden-
tify best practices or new options for full-time nonfam-
ily caregivers (volunteers, nursing organizations,
retired persons); and open communication channels
with payor representatives regarding alternative care-
giver support reimbursement.
Inpatient bed needs continue to increase beyond
some transplant centers’ capabilities. Building effi-
ciency, expertise, and logistics of posttransplant care
for patients can allow more patients to move through
a center’s outpatient program. Recommendations to
increase capacity in the outpatient setting included: as-
sess best practices for transitioning patients from inpa-
tient to outpatient care; expand outpatient service
models to include posttransplant monitoring via close,
temporary housing for patients/families; and seek re-
imbursement solutions for outpatient services.
Increased HCT patient volume will require inter-
dependency among transplant physicians and other
subspecialty professionals. For example, subspecialty
professionals include but are not limited to infectious
disease, radiology, pathology, internal medicine, and
gastroenterology practitioners. To address these sys-
tem challenges, the Working Group recommended
the development of: best practices for urgent consulta-
tions with subspecialists; guidelines for inpatient and
outpatient consultation procedures; and partnerships
with subspecialty professionals outside of the trans-
plant facility.Financial Working Group
Within the initial scope of the Financial Working
Group were insurance benefits, reimbursement for
centers performing HCT and the unique issues pre-
sented by the various payor types. Upon further dis-
cussion and refinement of these issues, the working
group identified 3 financial barriers to focus on varia-
tion in transplant insurance benefits; problems with
obtaining authorization for patient treatment and/or
participation in clinical trials; and the codes used to
obtain reimbursement for transplant are not clear
and comprehensive.
Among various payors, private or public, insurance
benefits for transplant vary significantly and inade-
quate insurance coverage creates financial barriers for
patients [13]. Recommendations to address such varia-
tion included: develop model benefit packages/guide-
lines and campaign for adoption among payors;
support the Health Resources and Services Adminis-
tration Advisory Council on Blood Stem Cell Trans-
plantation efforts to define standard transplant
coverage indications; and conduct targeted outreach
to self-funded groups, medical excess loss insurers,and benefit consultants. Additionally, the Working
Group recommends that theNMDP continue tomon-
itor changes in insurance coverage that will be imple-
mented as part of the Affordable Care Act and
advocate for improved transplant benefits as part of
the Essential Benefits Set.
Patients frequently face difficulty in obtaining in-
surance approval to undergo transplant or to partici-
pate in clinical trials [17]. To improve access to
clinical trials, recommendations included: develop
a standardized checklist of materials to be included
with requests for coverage of clinical trial participation
and approval timeline; develop a guideline for cover-
age based on Medicare clinical trial coverage; encour-
age researchers to write protocols in a way that makes
it easier for payors to understand their value; and de-
velop education for stakeholders on the importance
and benefits of participation in HCT clinical trials.
All medical procedures are assigned diagnosis and
procedure codes utilized to claim reimbursement from
a payor. The codes associatedwith transplant do not ad-
equately capture all portions of the process and their de-
scriptions are often in need of updates or increased
clarity.TheWorkingGroupproposed a comprehensive
review of these codes to identify necessary changes.IMPLICATIONS
The synthesis of Year I Symposium presentations,
round table discussions, attendee polling results, and
program evaluations resulted in the identification of
priority areas to be addressed in the SCI Year II. These
priority initiatives include recommendations to:
 Investigate strategies to increase HCT workforce
recruitment, retention, and improve work/life bal-
ance across the physician, nursing, and APP work-
forces in the field of HCT. This aspect includes
women, racial/ethnic minorities, persons with dis-
abilities, and other individuals who have been un-
derrepresented in science and graduate schools
 Assess the impact of current State and Federal legis-
lation on the delivery of HCT
 Make available to hospital administrators data on
the norms in HCT staffing and bed capacity across
regions of the United States
 Raise awareness of the optimal timing for HCT
referral
 Identify and disseminate best practices for caregiver
support and education through all phases of trans-
plant
 Develop a set of model transplant insurance benefits
for payors
 Establish a Pharmacy Workforce Working Group
to ensure that oncologic pharmacists specializing
in HCT are engaged in meeting the expected work-
force need
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Capacity and Care Delivery ModelWorking Group
 Engage stakeholder organizations essential to
achieving Working Group outcomes for Year II
Areas for future HCT-related health services and
health policy research were identified during Year I de-
liberations and include: characterization of the HCT
healthcare provider workforce; validation of practice
models including best practices for provider-to-
patient ratios; evaluation of the impact of delays in in-
patient discharge because of the lack oftemporary
housing; assessment of current state and federal poli-
cies and their impact on care delivery in HCT; deter-
mination of the capacity of the HCT system to meet
the future demand for transplants.
To put this research agenda into practice, we
need to build collaborations with HCT focused-
organizations, clinicians, and academic institutions to
develop well-designed research that can be translated
into improved care delivery.
HCT in 2020 Symposium—Year II
In Year II, the Working Groups will continue to
meet via conference call from October 2010 through
September 2011 to move forward priority initiatives.
The SCI Steering Committee will continue to oversee
and provide input into activities of 7 working groups.
The Year II working groups were strategically modi-
fied to include: (1) Physician Workforce; (2) APP
Workforce; (3) Nursing Workforce; (4) Pharmacy
Workforce; (5) Facility Capacity and Care Delivery
Model; (6) Financial; and (7) Diversity and Health
Care Disparities. The decision was made by the SCI
SteeringCommittee to combine the Facilities/BedCa-
pacity and Care Delivery Model Working Groups and
incorporate 2 newWorking Groups, the Diversity and
Health Care Disparities and Pharmacy Workforce
WorkingGroups. TheDiversity andHealth Care Dis-
parities Working Group will develop strategies to in-
crease access to transplant across all ethnic, racial,
and socioeconomic groups for patients with appropri-
ate indications and to improve workforce diversity.
The Pharmacy Workforce Working Group will ad-
dress workforce capacity, recruitment, retention issues,
and educational needs of the HCT pharmacy work-
force. Additionally, the CIBMTR/NMDP Health
Services Research Program will follow trends in
HCT utilization and capacity over time and follow
metrics tomonitor achievement of specific Year I Sym-
posium recommendations.
The SCI Symposium Year II will be held Septem-
ber 14-15, 2011, where the expanded activities of the 7
WorkingGroups will be presented, findings discussed,
and recommendations evaluated and prioritized. A pri-
mary product will be a report containing findings and
recommendations that will act as an implementationblueprint for advancement. The SCI will continue in
2012 (Year III) to act on the final Working Group rec-
ommendations identified at the Year II Symposium.
Thus, the plan for SCI Year I was to conduct an as-
sessment of the factors that may impact the ability of
the system to achieve the goal of 10,000 HCT by
2015. The plan for Year II is to analyze data from
Year I and collect data required to facilitate informed
planning and implementation of recommended SCI
initiatives designed to reach this goal. In Year III, we
will further engage partnerships with stakeholders to
foster adoption of prioritized SCI initiatives identified
in Years I and II.ACKNOWLEDGMENTS
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